Efficacy and safety of iGlarLixi versus IDegAsp by baseline β-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D study.

AIMS: To compare the efficacy and safety of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with insulin degludec plus insulin aspart (IDegAsp) by β-cell function in exploratory analyses of the Soli-D study. MATERIALS AND METHODS: Soli-D was a 24-week, multicentre, randomised, open-label study in Chinese adults with uncontrolled type 2 diabetes (T2D) on oral antidiabetic drugs (OADs). We evaluated glycaemic efficacy, body weight, total insulin daily dose and hypoglycaemia outcomes with iGlarLixi versus IDegAsp by baseline fasting C-peptide and Homeostasis Model Assessment of β-cell function (HOMA-β) quartile measurements. RESULTS: Among 386 participants, change in glycated haemoglobin (HbA1c), fasting plasma glucose or postprandial glucose at Week 24 showed no interaction with fasting C-peptide or HOMA-β quartile. The difference in HbA1c change favoured iGlarLixi versus IDegAsp in fasting C-peptide quartile 1 (Q1; p = 0.045) and Q2 (p = 0.023) and HOMA-β Q1 (p = 0.025). The proportion of participants with HbA1c <7.0% (<53 mmol/mol) was higher with iGlarLixi in fasting C-peptide Q2 (p = 0.009) and HOMA-β Q1 (p = 0.013). Body weight benefits were observed with iGlarLixi in HOMA-β Q1 (p = 0.003). Total insulin daily dose was lower with iGlarLixi, showing interactions between C-peptide or HOMA-β quartile and insulin dose (U or U/kg; p <0.001 for all). The event rate for any hypoglycaemia and American Diabetes Association Level 1 hypoglycaemia was lower with iGlarLixi in HOMA-β Q1 (p = 0.040 and 0.037). CONCLUSIONS: iGlarLixi provides improved glycaemic control at lower insulin daily doses compared with IDegAsp, regardless of C-peptide or HOMA-β levels, in Chinese people with uncontrolled T2D on OADs.